Physician profile
Ann C Brewer
NPI 1235573114
$8,262.62
in general payments reported to CMS, 2019-2025
18 companies · $3,968 in 2025
The $3,968 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $234 · 2021: $254 · 2022: $755 · 2023: $1,152 · 2024: $1,457 · 2025: $3,968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,435 · Consulting Fee: $1,950 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,435.17 |
| Consulting Fee | $1,950.00 |
| Education | $191.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,176.78 | 2025 | Bimzelx |
| Abbvie INC. | $1,846.79 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Regeneron Healthcare Solutions, INC. | $849.73 | 2020-2025 | Dupixent |
| Leo Pharma INC. | $594.31 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $584.84 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $339.92 | 2020-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $258.51 | 2022-2025 | Sotyktu |
| Incyte Corporation | $256.41 | 2022 | |
| Sun Pharmaceutical Industries INC. | $237.38 | 2021-2025 | |
| Janssen Biotech, INC. | $228.79 | 2021-2025 | Stelara, Simponi Aria, Simponi |
| Amgen INC. | $222.62 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $160.08 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $139.15 | 2019-2023 | |
| Genentech USA, INC. | $122.73 | 2019 | |
| Arcutis Biotherapeutics, INC. | $117.59 | 2025 | Zoryve |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $59.05 | 2019-2024 | |
| Organon LLC | $49.56 | 2025 | Vtama |
| Dermavant Sciences, INC. | $18.38 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.